Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead investigational therapy, (Z)-Endoxifen. Company announcements frequently cover progress in breast cancer programs, regulatory interactions, intellectual property developments, and emerging opportunities in other serious diseases.
Investors following ATOS news can expect regular updates on clinical trials involving (Z)-Endoxifen, including studies in metastatic ER+/HER2- breast cancer, neoadjuvant treatment for premenopausal ER+/HER2- patients, breast cancer risk reduction strategies focused on mammographic breast density, and participation in the RECAST DCIS platform trial for hormone receptor–positive ductal carcinoma in situ. These releases often summarize trial design, early findings, and the potential implications for future registration strategies.
Atossa’s news also highlights regulatory milestones, such as FDA Type C meetings, Investigational New Drug (IND) submissions, and “Study May Proceed” letters. Additional coverage includes the FDA’s Rare Pediatric Disease designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy, as well as AI-enabled research collaborations identifying new oncology indications like glioblastoma.
Another recurring theme in ATOS news is the company’s intellectual property position, including newly issued patents for enteric oral (Z)-Endoxifen formulations and methods of use in hormone-dependent breast disorders and estrogen-related conditions. Corporate updates, such as financial results, leadership appointments, and Nasdaq listing communications, provide context on Atossa’s operational and strategic direction.
By monitoring this news page, readers can review a chronological record of Atossa’s clinical, regulatory, scientific, and corporate announcements related to (Z)-Endoxifen and the company’s broader oncology and rare disease programs.
Atossa Therapeutics (Nasdaq: ATOS) announced the re-appointment of Drs. Mak Jawadekar, Per Hall, and Carl Novina to its Scientific Advisory Board (SAB) alongside the addition of Dr. Paul Wabnitz. The re-appointments are expected to strengthen Atossa's product development in oncology and infectious diseases, particularly in breast cancer and COVID-19. Dr. Wabnitz brings extensive clinical development experience, having worked on numerous oncology trials. This move aims to leverage their expertise to enhance Atossa's clinical programs and navigate challenges in drug development.
Atossa Therapeutics (Nasdaq: ATOS) reported its Q2 2022 financial results, highlighting key developments in their oncology and COVID-19 projects. The company completed dosing for AT-H201 in a Phase 1/2a trial aimed at hospitalized COVID-19 patients. Subsequently, they are shifting focus towards developing AT-H201 for cancer patients with lung damage from treatment. Financially, Atossa recorded operating expenses of $6,595, a 6% decrease from Q2 2021, with R&D expenses at $3,433, down 10%. Cash reserves stood at approximately $125,647, with no sustainable revenue reported.
Atossa Therapeutics (Nasdaq: ATOS) has completed dosing in Part C of its Phase 1/2a clinical study for AT-H201, an inhalation therapy aimed at treating lung injury from cancer treatments. The study involved administering two FDA-approved drugs in healthy volunteers. Due to evolving COVID-19 treatment landscapes, Atossa is shifting focus from COVID-19 to patients with lung injuries from radiation therapy, affecting 30-60% of cancer patients. The company plans to pursue this new development path and announce next steps in Q4 2022.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Charles Butler as vice president of investor and public relations, effective June 2, 2022. With 25 years of experience in healthcare communications, Butler previously led communications at Exelixis, contributing to over $1B raised. His expertise is expected to enhance Atossa’s communications strategy as the company continues to develop innovative treatments for breast cancer and COVID-19. The management anticipates that Butler will play a crucial role in conveying Atossa's message of innovation within a competitive market.
On May 18, 2022, Atossa Therapeutics (Nasdaq: ATOS) announced that CFO Kyle Guse will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The event takes place from May 23-26, 2022, at Fontainebleau Hotel in Miami Beach, FL, with Guse's presentation scheduled for May 24 at 12:30 PM ET. Attendees can request one-on-one meetings and register for both in-person and virtual participation.
Atossa focuses on developing innovative treatments for significant medical needs, particularly in oncology and infectious diseases.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported its Q1 2022 financial results, revealing no sustainable revenue and an operating loss of $4.7 million. Operating expenses rose 34% year-over-year to $4.7 million, primarily due to increased R&D expenses of $1.5 million and G&A expenses of $3.2 million, each reflecting heightened clinical trial activities. The company maintains cash reserves of approximately $131.6 million. Key advancements include a new U.S. patent for Endoxifen and the initiation of a Phase 2 study in premenopausal women with breast cancer, with an IND submission expected in Q2 2022.
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focusing on oncology and infectious diseases, will present at the Q2 Investor Summit Conference on May 3-4, 2022. Kyle Guse, CFO and General Counsel, will provide a corporate overview during the event. The presentation is scheduled for May 3, 2022, at 10:15 am ET. Investors can access the presentation through a webcast link and request one-on-one meetings.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has successfully completed participant enrollment for Part B of its Phase 1/2a clinical study of AT-H201 in Australia, focusing on inhalation therapy for COVID-19 patients and long-haulers. The study aims to investigate the efficacy of AT-H201 in improving lung function in both moderately to severely ill patients. While there’s a pressing need for additional therapies amid COVID-19 surges, the pathway to commercialization requires successful clinical outcomes and regulatory approvals. No assurances of success or approval are guaranteed.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced its participation in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. Management, including Dr. Steven Quay and Kyle Guse, will present a corporate overview on March 28, 2022, at 9:00 AM ET. Investors can view the presentation via the investor relations section of the company's website. Atossa is focused on developing innovative treatments for oncology and infectious diseases, particularly breast cancer and COVID-19.
Atossa Therapeutics (Nasdaq: ATOS) has announced the issuance of U.S. Patent No. 11,261,151, enhancing its intellectual property regarding Endoxifen, a therapy under development for breast cancer and related conditions. The patent, expected to expire in 2038, strengthens Atossa's position against generic competition. Atossa is advancing Endoxifen in two clinical studies: one for breast cancer treatment and another for addressing mammographic breast density, a significant public health issue affecting millions of women. The company plans to submit an IND to the FDA for further trials.
FAQ
What is the current stock price of Atossa Therapeutics (ATOS)?
What is the market cap of Atossa Therapeutics (ATOS)?
